Archive for June, 2008

New Survey Suggests Cultural Ambivalence To Allergies Leaves Many Suffering Needlessly

Monday, June 23rd, 2008

Indoor and outdoor allergies affect about 50
million people in the United States.(1)(2) Yet, according to "Attitudes
About Allergies," a national telephone survey, allergies are often
disregarded as a nuisance: in today’s society allergies get little respect.
As a result, allergy sufferers continue to cope needlessly with not only
the physical impact of allergies, but the emotional effects as well. The
survey was commissioned by Schering-Plough/MERCK Pharmaceuticals and
conducted by Harris Interactive(R). Three separate surveys were conducted:
a survey of more than 1,000 consumers, which included allergy sufferers and
non-allergy sufferers; a survey of more than 1,000 allergy sufferers only;
and a survey of 300 physicians.
The survey of consumers found that they view diabetes (81 percent),
hypertension or high blood pressure (76 percent) and arthritis (57 percent)
as more serious than indoor and outdoor allergies. Twenty-nine percent of
consumers said they view insomnia as more serious than indoor and outdoor
allergies. In addition, while the survey of consumers found that
seventy-eight percent feel sorry for allergy sufferers, more than a third
(36 percent) believe that allergy sufferers overstate the severity of their
symptoms and thirty percent say allergy sufferers use allergies as an
excuse to get out of something.
"Allergies are often disregarded in our society, making it acceptable
to tell allergy sufferers to ‘get on with it’ and not complain," said
Belinda Borrelli, PhD, associate professor, department of psychiatry and
human behavior, Brown Medical School and The Miriam Hospital. "But
allergies take an emotional toll on the sufferer. And despite that,
sufferers persevere, going to work, school and social engagements as if
nothing is wrong. Many don’t feel like it would be acceptable to call in
sick or change plans because of their allergies."
The survey of allergy sufferers found that about half (48 percent) feel
their spouse or significant other does not view their allergies to be a
serious health condition. Sufferers also perceive others as not taking
their allergies that seriously, saying their relatives (81 percent),
friends (86 percent) and co-workers (78 percent) view their allergies as a
somewhat serious or not serious health condition. Even their physicians,
they say, are ambivalent. The survey of allergy sufferers found that nearly
three quarters (74 percent) believe that their doctor views their allergies
as a somewhat serious or not serious health condition.
But clearly, that’s not the case. According to the survey of physicians
who treat allergies, a majority of physicians (84 percent) said in general,
patients do not overstate allergy symptoms. In addition, most physicians
view insomnia (83 percent) and osteoarthritis (69 percent) as being less
serious or equally as serious as allergies. Physicians report they view
diabetes (90 percent) and hypertension (84 percent) as being more serious
than allergies.
"Societal ambivalence toward allergies has impacted the management of
the disease," said David Lang, M.D., Section Head Allergy/Immunology
Buy viagra without prescription Respiratory Institute at Cleveland Clinic. "It’s true that allergies aren’t
life threatening, but they are quality of life-threatening on both physical
and emotional levels."
According to the survey of allergy sufferers, only about a third (34
percent) go to see a doctor for treatment when their symptoms are bothering
them.
"It’s absolutely crucial for allergy sufferers to begin a dialogue with
their physicians so that, together, they can address and overcome the
barriers keeping them from finding effective relief," said Jennifer
Derebery, M.D., clinical professor of otolaryngology at the Keck School of
Medicine, University of Southern California, Los Angeles.
The survey of allergy sufferers also shed new light on the often hidden
emotional impact of allergy symptoms. According to the survey, six in 10
sufferers (62 percent) report that their symptoms impact their mood. The
sufferer survey also found that when experiencing symptoms about half (51
percent) say they feel annoyed; forty-eight percent say they feel irritable
(48 percent); forty-two percent say they feel frustrated. And, two in 10
(22 percent) report that their allergy symptoms make them feel less
attractive; nineteen percent feel self-conscious (19 percent).
"We need to empower people with allergies to speak up and treat their
allergies as what they are — a medical condition that can have difficult
and sometimes debilitating effects," said Mike Tringale, director of
external affairs, Asthma and Allergy Foundation of America (AAFA). "Allergy
sufferers should feel comfortable talking about their symptoms with their
family, friends and healthcare providers."
For complete survey results, please visit

About Allergic Rhinitis
Allergic rhinitis affects more than 50 million people in the United
States(1)(2) and accounts for more than 14 million physician office visits
each year.(3) It is one of the most costly chronic illnesses in the United
States(4) and is estimated to cause 100 million days of lost work per
year.(5)
There are two forms of allergic rhinitis: seasonal and perennial.
Seasonal allergic rhinitis (often referred to as "hay-fever") occurs only
during certain times of the year and is commonly caused by allergies to
tree, grass and weed pollen. Perennial allergic rhinitis can occur
throughout the year and is caused by frequent exposure to allergens such as
animal
dander, indoor mold spores or house dust mites.(6)
Allergic rhinitis results when the immune system comes in contact with
an allergen, such as dust mites, animal dander or pollen, and mistakenly
identifies it as an intruder.(7) An allergic reaction results, involving
the body’s release of various inflammatory mediators, such as histamine and
leukotrienes, as a defense against the allergens, causing allergy symptoms
such as sneezing, nasal congestion, runny nose, and itching of the palate,
eyes and nose.(8)
About the Attitudes About Allergies Steering Committee
Guidance to the development of the survey was provided by the Attitudes
About Allergies Steering Committee including Belinda Borelli, PhD,
associate professor, department of psychiatry and human behavior, Brown
Medical School and The Miriam Hospital; Jennifer Derebery, M.D., clinical
professor of otolaryngology at the Keck School of Medicine, University of
Southern California, Los Angeles; David Lang, M.D., Section Head
Allergy/Immunology Respiratory Institute at Cleveland Clinic; and Mike
Tringale, director of external affairs, Allergy & Asthma Foundation of
America.
About the Attitudes About Allergies: Omnibus Survey
This survey was conducted by Harris Interactive on behalf of Schering-
Plough/MERCK Pharmaceuticals and is based on telephone interviews conducted
January 10 - 20, 2008 with 1,007 adults 18 years or older throughout the
United States including 551 with indoor or outdoor allergies and 454
without indoor or outdoor allergies. Two adults reported they did not know
if they had either indoor or outdoor allergies and were excluded from the
results. All telephone interviewing was conducted using random digit
dialing (RDD) methodology. The data are weighted to be representative of
U.S. adults 18 years of age or older. The sampling error for this survey is
plus or minus 3.2 percentage points at the 95 percent confidence level.
About the Attitudes About Allergies: Allergy Sufferer Survey
This survey was conducted by Harris Interactive on behalf of Schering-
Plough/MERCK Pharmaceuticals and is based on telephone interviews conducted
January 8 - 23, 2008, with 1,006 adults 18 years or older throughout the
United States who suffer from indoor or outdoor allergies. All telephone
interviewing was conducted using random digit dialing (RDD) methodology.
The data are weighted to be representative of U.S. adults 18 years of age
or older who have indoor or outdoor allergies. The sampling error for this
survey is plus or minus 3.2 percentage points at the 95 percent confidence
level.
About the Attitudes About Allergies: Physician Survey
This survey was conducted by Harris Interactive on behalf of Schering-
Plough/MERCK Pharmaceuticals and is based on telephone interviews conducted
January 8 - February 1, 2008, with 302 physicians who treat patients with
allergic rhinitis. The physician sample included 102 primary care
physicians, 100 allergists, and 100 otolaryngologists (ear, nose, and
throat specialists). The total sample of physicians was weighted to be
representative of the population of physicians in the U.S. who treat
patients with allergic rhinitis. The sampling error for this survey is plus
or minus 5.8 percentage points at the 95 percent confidence level.
About Harris Interactive(R)
Harris Interactive is one of the largest and fastest-growing market
research firms in the world. The company provides innovative research,
insights and strategic advice to help its clients make more confident
decisions which lead to measurable and enduring improvements in
performance. Harris Interactive is widely known for The Harris Poll(R), one
of the longest running, independent opinion polls, and for pioneering
online market research methods. The company has built what it believes to
be the world’s largest panel of survey respondents, the Harris Poll Online.
Harris Interactive serves clients worldwide through its North American,
European and Asian offices, and through a global network of independent
market research firms. More information about Harris Interactive may be
obtained at
References:
1 American Academy of Allergy Asthma & Immunology Topic of the Month:
March 2007: Spring & Allergic Rhinitis. Available at
Accessed August 1,
2007.
2 American Academy of Allergy Asthma & Immunology Tips to Remember:
Rhinitis. Available at
Accessed
August 1, 2007.
3 CDC. National Hospital Ambulatory Medical Care Survey: 2004 Emergency
Department Summary.
4 Goetzel R, et al. Health, absence, disability, and presenteeism cost
estimates of certain physical and mental health conditions affecting
U.S. employers. Journal of Occupational and Environmental Medicine.
2004;46:398-412.
5 Bellanti JA, Wallerstedt DB. Allergic rhinitis update: epidemiology and
natural history. Allergy Asthma Proc 2000;21:367-370.
6 American Academy of Allergy Asthma & Immunology Tips to Remember:
Rhinitis. Available at
Accessed
July 25, 2007
7 American Academy of Allergy Asthma & Immunology Tips to Remember:
Rhinitis. Available at
Accessed
July 25, 2007
Schering-Plough

Buy generic propecia | Generic diflucan pills no prescription | Buy lasix without prescription

Lyrica Reduced Pain Of Fibromyalgia In Patients Regardless Of Symptoms Of Anxiety Or Depression

Monday, June 23rd, 2008

Pfizer’s Lyrica reduced pain of fibromyalgia in patients regardless of whether they experienced symptoms of anxiety or depression at the beginning of the study, according to a pooled analysis presented today at the American Academy of Neurology annual meeting. The analysis, which looked at data pooled from previous clinical trials, also showed that patients’ self-reported improvements were more closely associated with improvements in pain and sleep than with improvements in fatigue or symptoms of anxiety or depression.
Fibromyalgia is the most common, chronic widespread pain condition in the United States and is thought to result from neurological changes in how patients perceive pain. Fibromyalgia is usually accompanied by poor sleep, stiffness and fatigue.
"The data showed that Lyrica reduced fibromyalgia pain, and alleviating that pain was associated with patients’ overall feeling of well-being," said Dr. Lesley Arnold, one of the study’s authors and associate professor in the department of psychiatry at the University of Cincinnati Medical Center. "Understandably, many patients with a chronic pain condition such as fibromyalgia also experience depression and anxiety, and importantly we found that Lyrica helped reduce pain in patients regardless of the presence of symptoms of these co-morbid conditions."
About the Analysis
Buy levitra without prescription The results are from a retrospective, pooled analysis of data from three placebo-controlled clinical trials (8 weeks, 13 weeks and 14 weeks long) of Lyrica in over 2,000 fibromyalgia patients. These studies randomized patients to receive Lyrica 150 mg, 300 mg, 450 mg or 600 mg or placebo. Patients were asked to measure their pain on a scale of zero to 10; the baseline score for study participants was 6.9 (150 mg, 450 mg, 600 mg) or 7.0 (300 mg). A score of 4.0 to 6.9 is considered moderate pain and a score of greater than 7.0 is considered moderate to severe pain on this 10-point scale.
In the studies, 38 percent of fibromyalgia patients had moderate to severe anxiety symptoms, while 27 percent had moderate to severe depressive symptoms, as assessed using the Hospital Anxiety and Depression Scales (HADS-A or HADS-D). Patients with severe depression or unstable psychiatric conditions were excluded from the studies.
The new analysis confirmed that Lyrica was significantly more effective than placebo in reducing pain in patients with fibromyalgia. Patients receiving 600 mg a day of Lyrica had a pain reduction of 2.08 on the pain scale; 450 mg a day had a reduction of 2.01; 300 mg a day had a reduction of 1.76; 150 mg a day had a reduction of 1.37, and placebo had a reduction of 1.25. Additionally, Lyrica was found to reduce pain in patients regardless of whether they had symptoms of anxiety or depression.
The analysis also examined the relationship between improvements in pain, sleep, fatigue, anxiety and depressive symptoms with patients reporting feeling "much improved" or "very much improved" as measured by the Patient Global Impression of Change (PGIC). The PGIC is a standardized, self-reported tool that measures the change in a patient’s overall status ranging from "very much improved" to "very much worse."
Pain reduction was found to have the greatest association on patients reporting improvement as measured by PGIC. The relationships between feeling much or very much improved were strongest for pain and sleep, and less pronounced for fatigue and symptoms of anxiety or depression, but statistically significant for all variables.
The most common side effects in the pooled analysis versus placebo of these three studies were dizziness and somnolence, followed by weight gain, blurred vision and dry mouth.
About Lyrica
In the United States, Lyrica® (pregabalin) capsules, CV, is approved for the management of fibromyalgia. Lyrica is also indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia (pain after shingles), and as adjunctive therapy for adults with partial onset seizures. The 600 mg/day is not an approved dosage for Lyrica in the management of fibromyalgia.
Important Safety Information
Lyrica is not for everyone. Lyrica may cause serious allergic reactions. Patients should tell their doctors right away about any serious allergic reaction such as swelling of the face, mouth, lips, gums, tongue or neck or if they have any trouble breathing. Other allergic reactions may include rash, hives and blisters. Patients should tell their doctors about any changes in eyesight, including blurry vision, muscle pain along with a fever or tired feeling, or skin sores due to diabetes.
Some of the most common side effects of Lyrica are dizziness, sleepiness, weight gain, blurred vision, dry mouth, feeling "high", swelling of hands and feet, and trouble concentrating. Patients may have a higher chance for swelling and hives if they are also taking angiotensin converting enzyme (ACE) inhibitors so they should let their doctors know if they are taking these medications. They may have a higher chance of swelling or gaining weight if they are also taking certain diabetes medicines.
Patients should not drive a car or operate machinery until they know how Lyrica affects them. Patients should not drink alcohol while on Lyrica. Patients should be especially careful about medicines that make them sleepy and should also tell their doctors if they are planning to father a child. Patients should tell their doctor if they are pregnant, plan to become pregnant, or are breast-feeding. If they have had a drug or alcohol problem, they may be more likely to misuse Lyrica. Patients should talk with their doctor before they stop taking Lyrica, or any other prescription medication. Lyrica is one of several treatment options for doctors to consider.

View drug information on Lyrica.
Generic viagra pills no prescription | Buy generic ultram | generic levitra online buy

Suicide Prevention Group Delivers Much Needed Message To Pennsylvania’s Elderly

Monday, June 23rd, 2008

Latest News For Seniors / Aging
Suicide Prevention Group Delivers Much Needed Message To Pennsylvania’s Elderly
17 May 2008
Stroke Patients At Greater Risk For Falls
17 May 2008
Inspectors Often Overlook Serious Deficiencies At U.S. Nursing Homes, GAO Report Finds
16 May 2008
View more news…
Latest Videos for Seniors
Cholesterol Management
Each year more than a million Americans have heart attacks. High cholesterol is a major risk factor for heart attack and stroke. Lifestyle changes and adherence to a treatment plan are important for cholesterol management…
Diagnosing Alzheimer’s Early
Early diagnosis
of Alzheimer’s disease is critical to delaying the effects of the disease. Additonally, the earlier the diagnosis, the more time patients and caregivers have to plan for the future…
Buy cialis pills View more videos…
Advertisements
Add Your Advertisement Here
Most Read Articles From The Last 7 Days
Depressed Teenagers Making Themselves Worse With Marijuana Says US Government Report
12 May 2008
Benefits In Chronic Pain Outweigh Risks For Painkiller Abuse
12 May 2008
Evidence Discovered For Suspected Cause Of Type 1 Diabetes
12 May 2008
Pollution Linked To Deep Vein Thrombosis And Blood Clots
13 May 2008
Mind: Return Of The Great Depression Causing Great Depression
12 May 2008
Most Popular Categories
public health
neurology
nutrition
cancer
cardiovascular
hiv
diabetes
dermatology
obesity
alcohol
psychology
women’s health
infectious diseases
pediatrics
breast cancer
urology
pregnancy
gastrointestinal
pain
respiratory
prostate

bones
depression
smoking
medical devices
health insurance
medicare
hypertension
stem cell research
biology
alzheimer’s
sexual health
sleep
abortion
genetics
allergy
autism
eye health
adhd
it
multiple sclerosis
sports medicine
pharma industry
dentistry
liver disease
anxiety
arthritis
seniors

cholesterol
mrsa
generic viagra online buy | Buy generic lexapro | Buy zithromax without prescription

Precision Blood Pressure Measurement To Improve Heart Health

Monday, June 23rd, 2008

Latest News For Hypertension
Sleep-Related Breathing Disorders Affect Children’s Blood Pressure During Sleep
13 Jun 2008
Precision Blood Pressure Measurement To Improve Heart Health
13 Jun 2008
Study
Links High Normal Blood Pressure To Significant Cardiovascular Risk - Atcor Medical’s SphygmoCor System Plays Key Role In Discovery
13 Jun 2008
View
more news…
Most Read Articles From The Last 7 Days
Boy Dies Of Dry Drowning After Leaving Pool And Walking Home
06 Jun 2008
Vitamin D May Help Prevent Heart Attacks
10 Jun 2008
Intensive Control Of Blood Sugar Does Not Reduce Heart Risk In Type 2 Diabetes
09 Jun 2008
FDA Expands Salmonella In Raw Red Tomatoes Warning
09 Jun 2008
Decline In Teen Sex, Increase In Condom Use Level Off, CDC Study Says
06 Jun 2008
Latest Videos for Hypertension
Medications and Diet for hypertension
Hypertension or high blood pressure is a risk factor for heart disease, stroke and other cardiovascular conditions. Fortunately, it can be controlled. Tune in to find out how…
Diabetes and Hypertension
Controlling blood sugar levels are crucial for people with diabetes. But equally important is blood pressure control. generic propecia online buy High blood pressure and diabetes often occur together and if left untreated can lead to serious consequences. Join experts as they discuss the link between these two conditions, who…
View more videos…
Most Popular Categories
cancer
cardiovascular
dermatology
hiv
nutrition
diabetes
obesity
pediatrics
psychology
neurology
alcohol
urology
breast cancer
women’s health
infectious diseases
respiratory
sexual health
gastrointestinal
pain
pregnancy
bones
medical devices
medicare
depression
prostate
smoking
alzheimer’s
allergy
sleep
biology
genetics
eye health

sports medicine
hypertension
abortion
health insurance

autism
stem cell research
adhd
liver disease

multiple sclerosis
arthritis
pharma industry
seniors
dentistry
it
nursing

blood
fertility
Buy zithromax without prescription | Generic viagra pills no prescription | Generic soma pills no prescription

BrainCells Inc. Initiates Phase 2 Clinical Trial With BCI-540 For Depression With Anxiety

Monday, June 23rd, 2008

BrainCells Inc. (BCI), a
biopharmaceutical company utilizing its platform technology to identify and
develop compounds that promote the growth of new neurons for the treatment
of central nervous system (CNS) diseases, announced that it has
initiated a Phase 2a clinical trial with its lead product candidate,
BCI-540, for the treatment of depression with anxiety.
"We are encouraged by the enthusiasm expressed by our clinical
investigators who
view BCI-540 as a potential alternative to today’s widely
prescribed treatments for depression," noted Carrolee Barlow, M.D., Ph.D.,
Chief Scientific Officer at BCI. "Current therapies directly impact
serotonin levels causing many unpleasant side effects, however we have
shown that BCI-540 directly impacts neurogenesis without affecting
serotonin levels. We are excited about the potential of this compound to
change the way mood disorders are treated."
The twelve-week randomized double-blind, placebo-controlled study will
evaluate safety, efficacy and tolerability of BCI-540 to determine whether
80 mg given once or three times daily is effective in the treatment of
depression with anxiety versus placebo.
"BCI is utilizing our understanding of the power of neurogenesis
coupled with our proprietary neurogenic platform technology to identify a
strong portfolio of clinical candidates, such as BCI-540, that we plan to
move into the clinic this year," said Jim Schoeneck, CEO at BCI. "Moving
BCI-540 into the clinic is an important milestone and we are now actively
enrolling patients and anticipate completing enrollment by the end of this
year."
About BrainCells Inc.
BrainCells Inc. (BCI) is a San Diego-based drug discovery and
development company that is applying its proprietary neurogenesis platform
technology to identify and reposition compounds for the treatment of
central nervous system (generic clomid online buy CNS) diseases. Neurogenesis is the process by which
endogenous stem cells in the adult human brain produce new brain tissue,
including neurons. With its predictive screening platform, BCI can direct
the selection and development of neurogenic compounds, increasing the
opportunity for successful clinical trials in a variety of CNS indications.
For more information, visit
BrainCells Inc.

Buy generic cialis | Buy diflucan pills | generic ultram online buy